Obesity

Semaglutide may help reduce the need for antihypertensive, lipid-lowering therapy

February 11, 2025

Study details: This post hoc analysis pooled data from five randomized controlled STEP trials to evaluate the impact of semaglutide 2.4 mg on the use of antihypertensive and lipid-lowering treatments in participants with overweight or obesity, with and without T2DM. The trials included were STEP 1, 3, 6, and 8 for the general population and STEP 2 and 6 for those with T2DM.

Results: A higher proportion of participants in the semaglutide 2.4 mg group experienced a reduction in the intensity of antihypertensive and lipid-lowering treatments compared with placebo. Additionally, fewer participants in the semaglutide group required intensification of these treatments. Significant weight loss was observed in the semaglutide group, contributing to these outcomes.

Clinical impact: Semaglutide 2.4 mg appears to not only aid in weight reduction but to also reduce the need for antihypertensive and lipid-lowering medications in patients with overweight or obesity.

Source:

Tchang BG, et al. (2025, February). Obesity (Silver Spring). Effect of semaglutide 2.4 mg on use of antihypertensive and lipid-lowering treatment in five randomized controlled STEP trials. https://pubmed.ncbi.nlm.nih.gov/39756397/